Maximum quantity allowed is 999
请选择数量
CAS RN: 192927-63-2 | 產品號碼: M2479
Moxifloxacin Hydrochloride Monohydrate
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | M2479 |
純度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__2__1H__2__4FN__3O__4·HCl·H__2O = 455.92 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| 包裝和容器
|
100MG-Glass Bottle with Plastic Insert （閲覽圖片）, 1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 192927-63-2 |
| 相關CAS RN
|
186826-86-8&151096-09-2 |
| Reaxys-RN | 8377447 |
| PubChem Substance ID | 354334556 |
| Merck Index(14) | 6291 |
| MDL編號 | MFCD00949117 |
產品規格
| Appearance | White to Orange to Green powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | -124 to -137 deg(C=0.5, water) |
| Water | 3.0 to 5.0 % |
性質
| 熔點 | 240 °C(dec.) |
| Maximum Wavelength | 338 nm (H__2O) |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H341 : Suspected of causing genetic defects. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
相關法規
| RTECS # | VB1983750 |
運輸資料
| HS編碼* | 2933.49-000 |
Application
Moxifloxacin Hydrochloride: A Fluoroquinolone Antibacterial with a Methoxy Group in the C-8 Position
Moxifloxacin hydrochloride (BAY 12-8039) is a synthetic fluoroquinolone antibacterial agent with in vitro activity against a wide range of Gram-positive and Gram-negative bacteria. The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) in Gram-negative bacteria and topoisomerase IV in Gram-positive bacteria required for bacterial DNA replication, transcription, repair, and recombination. It is reported that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. Therefore, moxifloxacin has improved activity against Gram-positive species (including staphylococci, streptococci, enterococci) compared with ciprofloxacin [ C2510, C2227 (HCl salt)]. Recently, antituberculosis activity of moxifloxacin has been reported. (The product is for research purpose only.)
References
- 1)In vitro Activity of BAY 12-8039, a New 8-Methoxyquinolone
- 2)The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus
- 3)In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
- 4)Moxifloxacin: A review of its use in the management of bacterial infections
- 5)Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching
- 6)Optimization of separation and determination of moxifloxacin and its related substances by RP-HPLC
- 7)Solubility of Antibiotics in Different Solvents. 1. Hydrochloride Forms of Tetracycline, Moxifloxacin, and Ciprofloxacin
考研文獻
文檔
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。